ACE Oncology’s Post

Advances on target therapy and biomarkers

Not only are quantitative changes in ctDNA levels important for MRD and disease surveillance, now the actual kinetics may indicate suggested therapeutic routes. It’s a very small sample pool, but it’s exciting to see diagnostics becoming more and more crucial in the physician decision making pathway. #precisionmedicine

https://lnkd.in/guFAkXAR ctDNA is a promising biomarker in cancer care. It’s used in clinical trials to: 1. Detect cancer non-invasively, offering insights into tumor genetics. 2. Monitor treatment response, guiding personalized therapy adjustments. 3. Design trials more effectively, potentially serving as a surrogate endpoint for treatment efficacy.

Quantitative detection of #BCR-ABL1 (p210) fusion gene is crucial in the diagnosis and treatment of chronic myeloid leukemia (#CML). The BCR-ABL1 (p210) % IS Kit, developed by Sniper Medical Technologies, provides accurate and reliable results for medication, efficacy evaluation, and prognosis monitoring. This kit has received #CE IVD and #FDA 510 (k) approvals and offers absolute quantification of the BCR-ABL1 gene without standards. With a LOD MR4.5 (single well) and MR5.0 (dual wells), the kit offers high sensitivity and a wide detection range, compatible with both e13a2 and e14a2 transcript variants. The #DQ24 fully automatic integrated digital PCR system simplifies the process with a one-step method, making it easy to use. The results provide %IS and MR values directly, making interpretation intuitive. Get accurate results with the BCR-ABL1 (p210) % IS Kit from Sniper Medical Technologies.

At MitogenDx, we leverage cutting-edge technologies to advance diagnostic capabilities across diverse medical disciplines. Our offerings include: Simoa™ Based Assays: Achieve unparalleled sensitivity with femtogram-level biomarker detection across multiple sample types. Perfect for autoimmunity, inflammation, and oncology. Line Immunoassays (LIA): Differentiate antibody reactivity to multiple antigens on a single test strip, providing comprehensive antibody profiling with high specificity. Cell Based Assays: Utilize transfected cells to detect antibodies against specific antigens, enabling multiplexing and precise antibody identification. Luminex Assays: Employ microsphere-based technology for high-throughput, multiplex detection of analytes, ensuring rapid and accurate bioanalysis. Explore how these technologies are transforming diagnostics at MitogenDx. Learn more on this page: https://lnkd.in/dZREFm4T #MitogenDx #DiagnosticInnovation #HealthcareTechnology #PrecisionMedicine #Bioanalysis #ClinicalDiagnostics #MedicalResearch #Diagnostics

With the FDA and EMA approval of Updualag; the combo of PD-1 and Lag-3 blocking Abs, I think this beautiful paper needs another posting. Why?? Well, I think further dissemination of the data, would be helpful since in several even recent papers the mechanism of action of Lag-3 blockade is still discussed with a focus mainly on Hla Class II as the main ligand, and speculations focus on the lacking expression on cancer cells. Hla Class II is the first Lag-3 ligand described more than 30 years ago, and several other ligands have been suggested since. However, the paper by Guy et al., from the Vignali lab, provides some important info on the mechanism of action when it comes to Lag-3 blocking. Thus, it is very nicely shown that Lag-3 binds to the T cell receptor (TCR) on the T cell itself, i.e., in cis, and acts by hindering the CD4/8 co-stimulatory signal. Importantly, there is no need for a ligand on the target cell. Thus, the efficacy of Lag-3 blockade, of which numerous molecules are still in clinical testing, would most likely depend on blocking the interaction between the TCR and Lag-3. The clinical data from Updualag, although still early, suggests that it is as effective as the PD-1/CTLA-4 combo, but with milder side effects. If that is maintained as the data matures, that would pave the way for a more widely applicable combo, e.g., also potentially in the neo-adjuvant setting. Time will tell.  https://lnkd.in/dZ69EbEi

We WILL, will YOU? - Biomarkers 2024 UK Congress! 😃 👉 How would 100 times higher sensitivity change biomarker discovery, clinical trials and patient outcome? We are eager to discuss with you. 👨🔬 👩🔬 📍 Biomarkers 2024 UK, London (#BiomarkersSeries24) 📅 Date: 29 Feb - 01 Mar 🖼️ Poster: "Non-invasive patient stratification and treatment follow-up using ctDNA in CRC patients and Lung cancer patients" Join us at the poster presentation to discover how our ultra-sensitive superRCA technology extend the possibilities in liquid biopsy and cfDNA analysis, used through-out biomarker discovery, clinical trials and patient monitoring. 🧪 We'll be presenting data and insights, including comparisons between solid tissue gDNA and plasma cfDNA in colorectal cancer patients, and relapse monitoring in lung cancer patients, using multiplex panels. 🧬 Looking forward to meet with you and discuss how we through collaborations and services can make precision medicin reach the patients faster! Lei Chen, Co-founder and CTO Alexander Kele, Director Business Development Visit our website for more information on our attendance: https://lnkd.in/dRxVnd3a #BiomarkersSeries24 #Biomarkers #PrecisionMedicine #BiomarkerResearch

It is always good to go back to the basics. I was trying to refresh my knowledge on the advancement of CAR-T therapy and I found this old blogpost from Crown Bioscience that answered the top 13 questions from a webinar presentation by Dr Rajendra Kumari. It is great to see how far we have come in our ability to leverage the complexities of organoids in evaluating CAR-Ts and other immuno-related therapies. #immunotherapy #organoids #CAR-T https://lnkd.in/eUQKzzqC

Quantitative detection of #BCR-ABL1 (p210) fusion gene is crucial in the diagnosis and treatment of chronic myeloid leukemia (#CML). The BCR-ABL1 (p210) % IS Kit, developed by Sniper Medical Technologies, provides accurate and reliable results for medication, efficacy evaluation, and prognosis monitoring. This kit has received #CE IVD and #FDA 510 (k) approvals and offers absolute quantification of the BCR-ABL1 gene without standards. With a LOD MR4.5 (single well) and MR5.0 (dual wells), the kit offers high sensitivity and a wide detection range, compatible with both e13a2 and e14a2 transcript variants. The #DQ24 fully automatic integrated digital PCR system simplifies the process with a one-step method, making it easy to use. The results provide %IS and MR values directly, making interpretation intuitive. Get accurate results with the BCR-ABL1 (p210) % IS Kit from Sniper Medical Technologies.

Great working with our partners at the Universitätsklinikum Erlangen and the Fraunhofer Institute for Interfacial Engineering and Biotechnology on this biomarker discovery project! By leveraging cell-free DNA methylation #data, we used #GenedataProfiler to develop an unbiased #machinelearning approach to discriminate #pancreaticcancer patients from other patient subgroups.    You can find the publication here: https://lnkd.in/eUiuB2zh   #ArtificialIntelligence #PathToPrecision